Leap Therapeutics Inc (LPTX.OQ)
16 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Leap Therapeutics Announces First Patient Dosed With TRX518 Combination Therapy
- BRIEF-Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders
- BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics as of Nov 14
- BRIEF-Leap Therapeutics announces $18 million private placement offering
- BRIEF-Leap Therapeutics qtrly loss per share $0.73